Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy |
Shin, Ho-Cheol
(Department of Hematology/Oncology, Kyungpook National University Hospital)
Lee, Yoo-Jin (Department of Hematology/Oncology, Kyungpook National University Hospital) Moon, Joon-Ho (Department of Hematology/Oncology, Kyungpook National University Hospital) Lee, Soo-Jung (Department of Hematology/Oncology, Kyungpook National University Hospital) Kang, Byung-Woog (Department of Hematology/Oncology, Kyungpook National University Hospital) Chae, Yee-Soo (Department of Hematology/Oncology, Kyungpook National University Hospital) Kim, Jong-Gwang (Department of Hematology/Oncology, Kyungpook National University Hospital) Choi, Jun-Young (Department of Hematology/Oncology, Kyungpook National University Hospital) Seo, Jong-Won (Department of Hematology/Oncology, Kyungpook National University Hospital) Kim, Yu-Kyung (Department of Laboratory Medicine, Kyungpook National University Hospital) Suh, Jang-Soo (Department of Laboratory Medicine, Kyungpook National University Hospital) Sohn, Sang-Kyun (Department of Hematology/Oncology, Kyungpook National University Hospital) |
1 | Shulman HM, Luk K, Deeg HJ, Shuman WB, Storb R. Induction of hepatic veno-occlusive disease in dogs. Am J Pathol 1987;126:114-125. |
2 | Terenzi A, Aristei C, Aversa F, et al. Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: preliminary results. Transplant Proc 1996;28:3101. |
3 | Chun HG, Leyland-Jones B, Cheson BD. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 1991;9:175-188. DOI |
4 | Chae YS, Sohn SK, Kim JG, et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone Marrow Transplant 2007;40:541-547. DOI ScienceOn |
5 | Iravani M, Evazi MR, Mousavi SA, et al. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients. Bone Marrow Transplant 2007;40:105-110. DOI ScienceOn |
6 | Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-828. |
7 | Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-217. DOI ScienceOn |
8 | Kim HJ, Chung IJ, Lee JJ, et al. A case of chronic graft-versus-host-disease following allogeneic peripheral blood stem cell rescue for poor graft function after bone marrow transplantation. Korean J Intern Med 1998;13:60-63. DOI |
9 | Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001;98:2942-2947. DOI ScienceOn |
10 | Giaccone L, Martin P, Carpenter P, et al. Safety and potential efficacy of low-dose methotrexate for treatment of chronic graftversus- host disease. Bone Marrow Transplant 2005;36:337-341. DOI ScienceOn |
11 | Copelan EA, Biggs JC, Avalos BR, et al. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia. J Clin Oncol 1992;10:237-242. DOI |
12 | Granados E, de La Camara R, Madero L, et al. Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation. Haematologica 2000;85:1060-1067. |
13 | Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89:3055-3060. |
14 | Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1997;20:909-913. DOI ScienceOn |
15 | Grochow LB, Krivit W, Whitley CB, Blazar B. Busulfan disposition in children. Blood 1990;75:1723-1727. |
16 | Schuler U, Schroer S, Kuhnle A, et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 1994;14:759-765. |
17 | Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerle J. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989;24:386-390. |
18 | Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002;8:493-500. DOI ScienceOn |
19 | Imamura M, Tanaka J. Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation. Korean J Intern Med 2009;24:287-298. DOI ScienceOn |
20 | Shah AJ, Lenarsky C, Kapoor N, et al. Busulfan and cyclophosphamide as a conditioning regimen for pediatric acute lymphoblastic leukemia patients undergoing bone marrow transplantation. J Pediatr Hematol Oncol 2004;26:91-97. DOI ScienceOn |
21 | Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/ maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008;111:1827-1833. DOI ScienceOn |
22 | Devergie A, Blaise D, Attal M, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxantotal body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 1995;85:2263-2268. |
23 | Ringden O, Labopin M, Tura S, et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia: Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996;93:637-645. DOI ScienceOn |
24 | Litzow MR, Perez WS, Klein JP, et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol 2002;119:1115-1124. DOI ScienceOn |
25 | Blaise D, Maraninchi D, Archimbaud E, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood 1992;79:2578-2582. |
26 | Socie G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001;98:3569-3574. DOI ScienceOn |
27 | Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 2003;32:543-548. DOI ScienceOn |
28 | Davies SM, Ramsay NK, Klein JP, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000;18:340-347. DOI |
29 | DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996;24:830-837. DOI ScienceOn |